ARCHIVES

Risk-Benefit Analysis Advised Prior To Hormone Therapy

This article is from The Cancer Letter archive.

Vol. 33 No. 8 | August 27, 2010

Download PDF Visit The Full Archive

Related Articles

On “Day One Of Post-Genome World,” Eric Lander Recounts 15-Year Journey.

February 16, 2001

NCI Pilot to Speed Phase III Trials Deemed Unsuccessful, Will Be Shut Down

November 22, 2002

FDA Offers Grants For Conferences

May 1, 1987

To Review Cancer Bioinformatics Grid

November 12, 2010

Letter: No Intent To Link Flags With NSABP Inquiry, ORI’s Bivens Writes

March 10, 1995

In Brief: Three Centers Win Comprehensive Designation; Hiatt Named Deputy Director, NCI Cancer Control

October 31, 1997